Attovia Therapeutics, Inc.
ATTO
$19.49
$0.311.59%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | 41.06% | ||||
| Gross Profit | -41.06% | ||||
| SG&A Expenses | -24.46% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 23.91% | ||||
| Operating Income | -23.91% | ||||
| Income Before Tax | -23.13% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -23.13% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -23.13% | ||||
| EBIT | -23.91% | ||||
| EBITDA | -23.51% | ||||
| EPS Basic | -12.86% | ||||
| Normalized Basic EPS | -12.85% | ||||
| EPS Diluted | -12.86% | ||||
| Normalized Diluted EPS | -12.85% | ||||
| Average Basic Shares Outstanding | 9.10% | ||||
| Average Diluted Shares Outstanding | 9.10% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||